Company intelligence / Profile preview

Laboratoire du Lactéol

Houdan, Île-de-France, Francelacteol.com ↗

Ownership: Private
Development stage: Commercial

Overview

Multiple clinical trials over decades demonstrate that the company's lead product (Lactobacillus LB postbiotic) is effective in reducing duration/severity of acute diarrhea. It is widely used as an OTC or prescription digestive aid in over thirty countries.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Postbiotics
Industry: Biotech

Drug pipeline

4 assets

ZENPEP

Commercial

Indications: Exocrine pancreatic insufficiency

3 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; global distribution partners likely due to presence in >30 countries.

Beyond the preview

Go deeper on Laboratoire du Lactéol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laboratoire du Lactéol.

Explore the full profile